Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

VIP Research Guide: Vasoactive Intestinal Peptide and Its Receptors

Understand Hero VIP, the peptide behind the abbreviation, its receptor-research background, and how identity and assay conditions shape laboratory comparisons.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name VIP
Expanded name Vasoactive intestinal peptide
Literature peptide length 28 amino acids
Research receptors VPAC1 and VPAC2
Exported sizes 5 mg and 10 mg
Hero product VIP

VIP stands for vasoactive intestinal peptide. The abbreviation names a peptide with a long research history, not a single guaranteed response in every biological system. For laboratory work, its receptor context and the identity of the supplied material are more useful than a broad list of proposed effects.

Hero’s supplied export lists VIP in 5 mg and 10 mg formats. This guide explains the discovery background, the VPAC receptor distinction, and the evidence needed to connect a published experiment to a clearly documented research sample.

VIP. View catalog product

Origin story: an intestinal discovery with a broader research history

Said and Mutt reported isolation of a 28-residue peptide from porcine small intestine in 1970. The work introduced the material later known as VIP and described biological observations in the tested experimental systems (Said and Mutt, 1970).

A discovery origin does not determine the source of every modern sample. A synthetic research material and an isolated biological preparation should each be described using their actual specifications. The historical paper is not a manufacturing certificate for Hero’s product.

The expanded name also helps with a literature search. Search both VIP and vasoactive intestinal peptide, and verify that the result concerns the peptide rather than an unrelated use of the abbreviation. Then record the exact test material and model.

How VIP research works: distinguish VPAC1 and VPAC2

VIP receptor research distinguishes VPAC1 and VPAC2. A primary structure-activity study examined residues involved in interaction with both human receptors and development of a selective VPAC1 agonist. The comparison illustrates how structural changes can affect receptor pharmacology (Nicole et al., 2000).

A receptor-family label should therefore be followed by the subtype and expression system. An observed response does not independently identify which receptor contributed if the experimental design does not distinguish them.

A binding assay and a functional signaling assay answer different questions. A functional experiment might measure a second messenger, while another system measures a later cell or tissue response. Retain the actual endpoint rather than calling every measurement binding strength.

The GPCR guide provides background on receptor signaling. It helps explain why a concentration-response curve depends on both the test material and the system used to measure the response.

Key studies: discovery and structure-activity questions

Source Research setting Contribution Boundary
Said and Mutt, 1970 Peptide isolation and experimental characterization Historical discovery and peptide-length context Not identity or potency testing of a current supplier lot
Nicole et al., 2000 Human VPAC1/VPAC2 structure-activity research Residue contributions and selective-analog investigation Findings about a modified analog do not automatically describe native VIP
Lot characterization The supplied research material Stated identity and reported analytical properties Not a complete receptor or clinical evaluation

Structure-activity studies are especially useful when the comparison is explicit. Changing a residue asks how that structural change affects a defined measurement. It does not establish that every molecule with the same family name will produce the same result.

When reading an analog paper, distinguish native-sequence VIP, substituted peptides, and selective reference compounds. A selective analog is not interchangeable with the parent peptide simply because both appear in the same receptor experiment.

Keep the comparator, concentration units, assay conditions, and outcome definition beside each result. An apparent disagreement may reflect different systems or preparations rather than a simple contradiction about the peptide.

Weak spots: receptor activity is only part of the question

A target-level signal does not establish an organism-level benefit. Wider physiological responses depend on exposure, tissue context, and additional biological variables. A receptor experiment should be described using the target and model it actually evaluated.

As of November 17, 2026, this guide does not establish an approved clinical use for Hero VIP. It does not transfer an indication or a result from a separately formulated medicine or investigational product to Hero’s laboratory sample.

The export provides the VIP name and nominal sizes, but not a complete sequence certificate, terminal specification, or current lot result. Verify the material identity required by the method rather than assigning it from a general reference description.

Analytical purity is another separate question. A chromatographic result does not independently establish receptor potency, sterility, net content, or solution stability. Read the actual method and test scope before assigning those properties.

For a complex tissue model, define how receptor attribution will be tested. Without appropriate controls, a downstream signal alone may be insufficient to distinguish subtype contribution. A simple pathway diagram should not hide that experimental uncertainty.

Handling VIP in the lab

The 5 mg and 10 mg formats describe nominal material mass. Select preparation conditions from the actual lot documentation and the validated assay requirements. The discovery paper does not supply universal solvent conditions for every modern formulation.

For arithmetic only, nominal 5 mg at a final solution volume of 2 mL gives 2.5 mg/mL. Nominal 10 mg at the same final volume gives 5 mg/mL. These examples do not establish solvent compatibility or a suitable biological test concentration.

If the comparison requires molarity, confirm the appropriate molecular-weight basis for the supplied form. Equal masses of native VIP and a modified analog do not automatically represent equal molecule counts. Keep that distinction visible in the experimental plan.

The calculator and mass-conversion guide help check arithmetic. The COA guide explains the complementary analytical information needed for a reproducible materials record.

The half-life explainer distinguishes biological exposure from solution stability. A reported duration in an organism should not be repurposed as an expiry period for a stock prepared under different conditions.

Retain the product ID, lot, identity specification, solvent, final volume, preparation date, and dilution history. Assign only measured properties supported by the matching report. If a functional assay is required, report its controls and acceptance criteria separately from the chemistry tests.

VIP FAQ

What does VIP stand for?

Vasoactive intestinal peptide. The expanded name helps distinguish the compound from unrelated uses of the abbreviation.

Does VIP research involve only one receptor?

No. VPAC1 and VPAC2 are distinct receptor contexts. A useful study description identifies which system was tested.

Is a selective VIP analog the same material as VIP?

Not by assumption. Structural changes and receptor selectivity need to remain attached to the analog actually studied.

What is Hero VIP?

It is the VIP product in Hero’s supplied export, listed in 5 mg and 10 mg formats. Confirm exact sequence, form, and lot properties in the supplied documentation.

VIP. View catalog product

References

  1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-1218. Source.
  2. Nicole P, et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem. 2000;275(31):24003-24012. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack